Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Prelude Therapeutics

    NASDAQ: PRLD · Real-Time Price · USD
    0.98
    -0.02 (-1.99%)
    At close: Jun 05, 2025, 3:59 PM
    0.92
    -6.33%
    After-hours: Jun 05, 2025, 06:40 PM EDT

    Prelude Therapeutics Statistics

    Share Statistics

    Prelude Therapeutics has 56.46M shares outstanding. The number of shares has increased by 0.41% in one year.

    Shares Outstanding

    n/a
    		 56.46M

    Shares Change (YoY)

    n/a
    		 0.41%

    Shares Change (QoQ)

    n/a
    		 0.22%

    Owned by Institutions (%)

    n/a
    		 42.4%

    Shares Floating

    n/a
    		 n/a

    Failed to Deliver (FTD) Shares

    n/a
    		 9,725

    FTD / Avg. Volume

    n/a
    		 5.39%

    Short Selling Information

    The latest short interest is 877.74K, so 1.55% of the outstanding shares have been sold short.

    Short Interest

    n/a
    		 877.74K

    Short % of Shares Out

    n/a
    		 1.55%

    Short % of Float

    n/a
    		 11.89%

    Short Ratio (days to cover)

    n/a
    		 7.9

    Valuation Ratios

    The PE ratio is -0.76 and the forward PE ratio is -0.86. Prelude Therapeutics's PEG ratio is 0.04.

    PE Ratio

    n/a
    		 -0.76

    Forward PE

    n/a
    		 -0.86

    PS Ratio

    n/a
    		 13.75

    Forward PS

    n/a
    		 0.5

    PB Ratio

    n/a
    		 0.73

    P/FCF Ratio

    n/a
    		 -0.93

    PEG Ratio

    n/a
    		 0.04
    Financial Ratio History

    Enterprise Valuation

    Currently the Enterprise Value (EV) is not available for Prelude Therapeutics.

    EV / Sales

    n/a
    		 n/a

    EV / EBITDA

    n/a
    		 n/a

    EV / EBIT

    n/a
    		 n/a

    EV / FCF

    n/a
    		 n/a

    Financial Position

    The company has a current ratio of 5.3, with a Debt / Equity ratio of 0.14.

    Current Ratio

    n/a
    		 5.3

    Quick Ratio

    n/a
    		 5.3

    Debt / Equity

    n/a
    		 0.14

    Debt / EBITDA

    n/a
    		 -0.13

    Debt / FCF

    n/a
    		 -0.17

    Interest Coverage

    n/a
    		 0

    Financial Efficiency

    Return on Equity is n/a and Return on Invested Capital is n/a.

    Return on Equity

    n/a
    		 n/a

    Return on Assets

    n/a
    		 n/a

    Return on Invested Capital

    n/a
    		 n/a

    Revenue Per Employee

    n/a
    		 $53,435.11

    Profits Per Employee

    n/a
    		 $-970,786.26

    Employee Count

    n/a
    		 131

    Asset Turnover

    n/a
    		 0.04

    Inventory Turnover

    n/a
    		 n/a

    Taxes

    Income Tax

    n/a
    		 n/a

    Effective Tax Rate

    n/a
    		 0%

    Stock Price Statistics

    The stock price has increased by -74.8% in the last 52 weeks. The beta is 1.24, so Prelude Therapeutics's price volatility has been higher than the market average.

    Beta

    n/a
    		 1.24

    52-Week Price Change

    n/a
    		 -74.8%

    50-Day Moving Average

    n/a
    		 0.83

    200-Day Moving Average

    n/a
    		 1.53

    Relative Strength Index (RSI)

    n/a
    		 59.63

    Average Volume (20 Days)

    n/a
    		 180,446

    Income Statement

    In the last 12 months, Prelude Therapeutics had revenue of 7M and earned -127.17M in profits. Earnings per share was -1.68.

    Revenue

    n/a
    		 7M

    Gross Profit

    n/a
    		 5.23M

    Operating Income

    n/a
    		 -139.71M

    Net Income

    n/a
    		 -127.17M

    EBITDA

    n/a
    		 -139.71M

    EBIT

    n/a
    		 -139.71M

    Earnings Per Share (EPS)

    n/a
    		 -1.68
    Full Income Statement

    Balance Sheet

    The company has 12.47M in cash and 18.02M in debt, giving a net cash position of -5.55M.

    Cash & Cash Equivalents

    n/a
    		 12.47M

    Total Debt

    n/a
    		 18.02M

    Net Cash

    n/a
    		 -5.55M

    Retained Earnings

    n/a
    		 -583.56M

    Total Assets

    n/a
    		 141.26M

    Working Capital

    n/a
    		 82.62M
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was -102.89M and capital expenditures -764K, giving a free cash flow of -103.65M.

    Operating Cash Flow

    n/a
    		 -102.89M

    Capital Expenditures

    n/a
    		 -764K

    Free Cash Flow

    n/a
    		 -103.65M

    FCF Per Share

    n/a
    		 -1.37
    Full Cash Flow Statement

    Margins

    Gross margin is 74.69%, with operating and profit margins of -1995.91% and -1816.76%.

    Gross Margin

    n/a
    		 74.69%

    Operating Margin

    n/a
    		 -1995.91%

    Pretax Margin

    n/a
    		 -1816.76%

    Profit Margin

    n/a
    		 -1816.76%

    EBITDA Margin

    n/a
    		 -1995.91%

    EBIT Margin

    n/a
    		 -1995.91%

    FCF Margin

    n/a
    		 -1480.74%

    Dividends & Yields

    PRLD does not appear to pay any dividends at this time.

    Dividend Per Share

    n/a
    		 n/a

    Dividend Yield

    n/a
    		 n/a

    Dividend Growth (YoY)

    n/a
    		 n/a

    Payout Ratio

    n/a
    		 n/a

    Earnings Yield

    n/a
    		 n/a

    FCF Yield

    n/a
    		 n/a
    Dividend Details

    Analyst Forecast

    The average price target for PRLD is $4, which is 321.1% higher than the current price. The consensus rating is "Buy".

    Price Target

    n/a
    		 $4

    Price Target Difference

    n/a
    		 321.1%

    Analyst Consensus

    n/a
    		 Buy

    Analyst Count

    n/a
    		 3
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 n/a

    Lynch Upside

    n/a
    		 n/a

    Graham Number

    n/a
    		 n/a

    Graham Upside

    n/a
    		 n/a

    Scores

    Altman Z-Score

    n/a
    		 -7.82

    Piotroski F-Score

    n/a
    		 3

    Add to Watchlist